Call for a Global Vaccine Plan to Combat Current and Future Pandemics: One for ALL and ALL for One

Salim Surani; Pahnwat T. Taweesedt; Sara Surani; Iqbal Ratnani; Joseph Varon

doi:10.2174/18743064-v16-e2202040

Call for a Global Vaccine Plan to Combat Current and Future Pandemics: One for ALL and ALL for One

Salim Surani, Pahnwat T. Taweesedt, Sara Surani, Iqbal Ratnani, Joseph Varon

Research output: Contribution to journal › Article › peer-review

Abstract

The emergence of SARS-CoV-2 in late December 2019 has taken the world by storm. In March 2020, the World Health Organization (WHO) named this virus COVID-19. To date, it has infected approximately 186 million people worldwide and is attributed as the cause of death of more than 5 million people (and this number is only increasing.) The global effort to develop vaccines and therapeutics occurred at the fastest pace yet, with several vaccines' approval under emergency authorization use. There are also several post-marketing side effects, including myocarditis, cerebral venous embolism, and Guillain Barre Syndrome. Global vaccine disparity complicates the control of pandemic challenges. Several highly infectious variants have emerged, and more variants are feared to emerge if global vaccination plans are not developed soon.

Original language	English (US)
Article number	e187430642202040
Journal	Open Respiratory Medicine Journal
Volume	16
Issue number	1
DOIs	https://doi.org/10.2174/18743064-v16-e2202040
State	Published - 2022

Keywords

COVID-19
Cerebral venous embolism
Delta variant
Myocarditis
SARS-CoV-2
Vaccines
mRNA Vaccines

ASJC Scopus subject areas

Pulmonary and Respiratory Medicine

Access to Document

10.2174/18743064-v16-e2202040

Cite this

@article{efd288ed0725416d9f02ac1ea034c21b,

title = "Call for a Global Vaccine Plan to Combat Current and Future Pandemics: One for ALL and ALL for One",

abstract = "The emergence of SARS-CoV-2 in late December 2019 has taken the world by storm. In March 2020, the World Health Organization (WHO) named this virus COVID-19. To date, it has infected approximately 186 million people worldwide and is attributed as the cause of death of more than 5 million people (and this number is only increasing.) The global effort to develop vaccines and therapeutics occurred at the fastest pace yet, with several vaccines' approval under emergency authorization use. There are also several post-marketing side effects, including myocarditis, cerebral venous embolism, and Guillain Barre Syndrome. Global vaccine disparity complicates the control of pandemic challenges. Several highly infectious variants have emerged, and more variants are feared to emerge if global vaccination plans are not developed soon.",

keywords = "COVID-19, Cerebral venous embolism, Delta variant, Myocarditis, SARS-CoV-2, Vaccines, mRNA Vaccines",

author = "Salim Surani and Taweesedt, {Pahnwat T.} and Sara Surani and Iqbal Ratnani and Joseph Varon",

note = "Publisher Copyright: {\textcopyright} 2022 Surani et al.",

year = "2022",

doi = "10.2174/18743064-v16-e2202040",

language = "English (US)",

volume = "16",

journal = "Open Respiratory Medicine Journal",

issn = "1874-3064",

publisher = "Bentham Science Publishers Ltd.",

number = "1",

}

TY - JOUR

T1 - Call for a Global Vaccine Plan to Combat Current and Future Pandemics

T2 - One for ALL and ALL for One

AU - Surani, Salim

AU - Taweesedt, Pahnwat T.

AU - Surani, Sara

AU - Ratnani, Iqbal

AU - Varon, Joseph

PY - 2022

Y1 - 2022

N2 - The emergence of SARS-CoV-2 in late December 2019 has taken the world by storm. In March 2020, the World Health Organization (WHO) named this virus COVID-19. To date, it has infected approximately 186 million people worldwide and is attributed as the cause of death of more than 5 million people (and this number is only increasing.) The global effort to develop vaccines and therapeutics occurred at the fastest pace yet, with several vaccines' approval under emergency authorization use. There are also several post-marketing side effects, including myocarditis, cerebral venous embolism, and Guillain Barre Syndrome. Global vaccine disparity complicates the control of pandemic challenges. Several highly infectious variants have emerged, and more variants are feared to emerge if global vaccination plans are not developed soon.

AB - The emergence of SARS-CoV-2 in late December 2019 has taken the world by storm. In March 2020, the World Health Organization (WHO) named this virus COVID-19. To date, it has infected approximately 186 million people worldwide and is attributed as the cause of death of more than 5 million people (and this number is only increasing.) The global effort to develop vaccines and therapeutics occurred at the fastest pace yet, with several vaccines' approval under emergency authorization use. There are also several post-marketing side effects, including myocarditis, cerebral venous embolism, and Guillain Barre Syndrome. Global vaccine disparity complicates the control of pandemic challenges. Several highly infectious variants have emerged, and more variants are feared to emerge if global vaccination plans are not developed soon.

KW - COVID-19

KW - Cerebral venous embolism

KW - Delta variant

KW - Myocarditis

KW - SARS-CoV-2

KW - Vaccines

KW - mRNA Vaccines

UR - http://www.scopus.com/inward/record.url?scp=85127446783&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85127446783&partnerID=8YFLogxK

U2 - 10.2174/18743064-v16-e2202040

DO - 10.2174/18743064-v16-e2202040

M3 - Article

AN - SCOPUS:85127446783

SN - 1874-3064

VL - 16

JO - Open Respiratory Medicine Journal

JF - Open Respiratory Medicine Journal

IS - 1

M1 - e187430642202040

ER -

Call for a Global Vaccine Plan to Combat Current and Future Pandemics: One for ALL and ALL for One

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this